Berdazimer Topical Gel, 10.3%: First Approval.
Drugs
; 84(3): 363-368, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-38409574
ABSTRACT
Berdazimer topical gel, 10.3% (ZELSUVMI™) is a nitric oxide (NO) releasing topical gel developed by Novan Inc. (a Ligand Pharmaceuticals company) for the treatment of molluscum contagiosum (MC). Novan has used their proprietary NO-based technology platform (NITRICIL™), which stores gaseous NO species on large polymers, in the development of berdazimer topical gel, 10.3%. In January 2024, berdazimer topical gel, 10.3% was approved for the topical treatment of MC in adult and paediatric patients 1 year of age and older in the USA. This article summarizes the milestones in the development of berdazimer topical gel, 10.3% leading to this first approval for the treatment of MC.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Molluscum Contagiosum
Limits:
Adult
/
Child
/
Humans
Language:
En
Journal:
Drugs
Year:
2024
Document type:
Article
Affiliation country:
New Zealand